Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open Label, Dose Escalation Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors

NCT01139723 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01139723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01139723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open Label, Dose Escalation Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2010
Completion date
August 31, 2014
Enrollment
54 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

solid cancers